BIOCON2023-07-012023-09-30 BIOCON2023-07-012023-09-30 BIOCON2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member BIOCON2023-07-012023-09-30in-bse-fin:OneOperatingExpenses02Member BIOCON2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member BIOCON2023-07-012023-09-30in-bse-fin:FourOperatingExpenses02Member BIOCON2023-09-30 BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue01Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue02Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue03Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue04Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue01Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue02Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue03Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue04Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults01Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults02Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults03Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults04Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults01Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults02Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults03Member BIOCON2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults04Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets01Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets02Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets03Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets04Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2023-09-30in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2023-09-30in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2023-04-01 2024-03-31 2023-11-10 2023-10-09 INR Millions Half yearly 14:30:00 16:00:00 2023-11-10 2023-11-10 true Cash Flow Indirect Not applicable Multi segment 2023-07-01 2023-09-30 Unaudited Consolidated 34623000000.00 1579000000.00 36202000000.00 11660000000.00 3720000000.00 -4110000000.00 6224000000.00 2477000000.00 3893000000.00 9713000000.00 33577000000.00 2625000000.00 -240000000.00 2385000000.00 523000000.00 -107000000.00 416000000.00 0.00 1969000000.00 0.00 0.00 0.00 -242000000.00 1727000000.00 1903000000.00 3630000000.00 1256000000.00 471000000.00 2738000000.00 892000000.00 6003000000.00 5 1.05 1.05 0.00 0.00 1.05 1.05 Notes: 1.The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on November 9, 2023 and approved by the Board of Directors of the Company at their meetings held on November 10, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2.These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated November 10, 2023 for full notes to the financial results for quarter ended 30.09.2023. Multi segment 2023-04-01 2023-09-30 Unaudited Consolidated 68849000000.00 2514000000.00 71363000000.00 21916000000.00 6495000000.00 -5045000000.00 12017000000.00 4807000000.00 7473000000.00 18906000000.00 66569000000.00 4794000000.00 -240000000.00 4554000000.00 957000000.00 -193000000.00 764000000.00 0.00 3790000000.00 0.00 0.00 0.00 -574000000.00 3216000000.00 3612000000.00 6828000000.00 2270000000.00 946000000.00 4854000000.00 1974000000.00 6003000000.00 5 1.90 1.90 0.00 0.00 1.90 1.90 Less: Recovery of cost from co-development partners (net) -39000000.00 Other Expenses 9752000000.00 Less: Recovery of cost from co-development partners (net) -88000000.00 Other Expenses 18994000000.00 52950000000.00 76621000000.00 32600000000.00 163339000000.00 64730000000.00 41650000000.00 2431000000.00 0.00 14108000000.00 16539000000.00 3789000000.00 5802000000.00 405070000000.00 49108000000.00 17973000000.00 40332000000.00 6444000000.00 13445000000.00 0.00 2990000000.00 81184000000.00 10407000000.00 140699000000.00 545769000000.00 6003000000.00 183821000000.00 189824000000.00 242774000000.00 150073000000.00 40988000000.00 191061000000.00 1052000000.00 3807000000.00 3411000000.00 199331000000.00 28165000000.00 43925000000.00 21743000000.00 93833000000.00 5785000000.00 1686000000.00 2360000000.00 103664000000.00 302995000000.00 545769000000.00 Notes: 1.The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on November 9, 2023 and approved by the Board of Directors of the Company at their meetings held on November 10, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2.These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated November 10, 2023 for full notes to the financial results for quarter ended 30.09.2023. Biosimilars 19687000000.00 Generics 6764000000.00 Novel Biologics 0.00 Research Services 9101000000.00 Biosimilars 39835000000.00 Generics 13767000000.00 Novel Biologics 0.00 Research Services 17182000000.00 35552000000.00 70784000000.00 929000000.00 1935000000.00 34623000000.00 68849000000.00 Biosimilars -152000000.00 Generics 664000000.00 Novel Biologics 551000000.00 Research Services 1581000000.00 Biosimilars 91000000.00 Generics 1305000000.00 Novel Biologics 489000000.00 Research Services 2810000000.00 2644000000.00 4695000000.00 0.00 0.00 261000000.00 Notes: 1.The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on November 9, 2023 and approved by the Board of Directors of the Company at their meetings held on November 10, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2.These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated November 10, 2023 for full notes to the financial results for quarter ended 30.09.2023. 475000000.00 2383000000.00 4220000000.00 Biosimilars 424478000000.00 Generics 63221000000.00 Novel Biologics 2211000000.00 Research Services 58462000000.00 548372000000.00 -2603000000.00 545769000000.00 Biosimilars 250830000000.00 Generics 19849000000.00 Novel Biologics 408000000.00 Research Services 19553000000.00 290640000000.00 12355000000.00 302995000000.00 4807000000.00 -6695000000.00 -4224000000.00 0.00 -3476000000.00 0.00 0.00 0.00 0.00 -2750000000.00 0.00 0.00 0.00 7473000000.00 0.00 0.00 0.00 0.00 0.00 -158000000.00 0.00 866000000.00 402000000.00 -678000000.00 0.00 -112000000.00 0.00 -956000000.00 0.00 -7233000000.00 -2679000000.00 0.00 0.00 0.00 1096000000.00 0.00 -3775000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16000000.00 8369000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 633000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 438000000.00 0.00 -1401000000.00 0.00 -9949000000.00 0.00 0.00 0.00 0.00 0.00 0.00 252000000.00 3000000000.00 8039000000.00 404000000.00 116000000.00 0.00 2030000000.00 3866000000.00 0.00 0.00 4875000000.00 -8849000000.00 -99000000.00 -8948000000.00 12948000000.00 4000000000.00 Items that will not be re-classified to profilt or loss -87000000.00 Items that will not be re-classified to profilt or loss -74000000.00 -87000000.00 -74000000.00 -27000000.00 -23000000.00 Items that will be re-classified to profilt or loss 1862000000.00 Items that will be re-classified to profilt or loss 3891000000.00 1862000000.00 3891000000.00 -101000000.00 228000000.00